ATE367159T1

Immune response modifier compounds for treatment of th2 mediated and related diseases

Abstract

Immune response modifier compounds-imidazoquinoline amines, imidazopyridine amines, 6,7-fused cycloalkylimidazopyridine amines, and 1,2-bridged imidazoquinoline amines-are useful for the treatment of TH2 mediated diseases by administering a therapeutically effective amount of such compounds in order to inhibit TH2 immune response, suppress IL-4/IL-5 cytokine induction and eosinophilia, as well as enhance TH1 immune response.

Term

Term ended

Projected expiry passed 24 October 2017, 8.9 years ago.

  1. Priority
  2. Filed
  3. Published
  4. Projected expiry
  5. Today

2 priority claims, no other members on record

This recordMember, by publication datePriority claim

Priority claims2

Priority claims
DocumentOfficeKindDate
2930196United States of AmericaP
4533197United States of AmericaP